Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

NASH Clinical Trials

100 recruiting trials for NASH. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
100
Total Trials
100
Recruiting Now
7
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT05385237

Identification of Hepatic Fibrosis Using 4D-MRI

To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 2002 locations
RECRUITINGPhase 2NCT06661538

Implementing Food Referrals for Equity and Sustained Health

Food insecurity (FI) disproportionately affects those who have been historically marginalized and significantly contributes to poor health outcomes. In children, FI is associated...

Sponsor: University of California, San DiegoEnrolling: 6002 locations
RECRUITINGPhase 2NCT06863376

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is...

Sponsor: Tanta UniversityEnrolling: 461 location
RECRUITINGNCT06671886

NAFLD Clinical Care Pathway

Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure...

Sponsor: VA Office of Research and DevelopmentEnrolling: 321 location
RECRUITINGNCT05332613

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30...

Sponsor: Weill Medical College of Cornell UniversityEnrolling: 401 location
RECRUITINGPhase 2NCT05632861

HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.

Sponsor: Tasly Pharmaceutical Group Co., LtdEnrolling: 7620 locations
RECRUITINGPhase 3NCT06632457

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have...

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called...

Sponsor: Boehringer IngelheimEnrolling: 159020 locations
RECRUITINGNCT02863757

Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular...

Sponsor: Humanity and Health Research CentreEnrolling: 15001 location
RECRUITINGEarly Phase 1NCT06113003

The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease

Persons with human immunodeficiency virus (HIV) have higher risk of developing fatty liver disease (NAFLD) than HIV-negative persons but the reasons for this discrepancy are not...

Sponsor: Vanderbilt University Medical CenterEnrolling: 631 location
RECRUITINGNCT06571474

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic...

Sponsor: Bettina MittendorferEnrolling: 601 location
RECRUITINGNCT07070362

Digital Early Warning System for Acute Lung Injury in Liver Surgery

This study focuses on developing an explainable machine learning model based on cardiopulmonary interaction characteristics to achieve early prediction of acute lung injury (ALI)...

Sponsor: Beijing Tsinghua Chang Gung HospitalEnrolling: 40001 location
RECRUITINGNCT03572465

Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced...

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)Enrolling: 1021 location
RECRUITINGPhase 2NCT05424003

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver...

Sponsor: Virginia Commonwealth UniversityEnrolling: 501 location
RECRUITINGNCT06888310

Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 4081 location
RECRUITINGNCT06508190

Free Walking Exercise in Obstructive Sleep Apnea Patients With Non-alcoholic Fatty Liver

Research evaluating the impact of continuous positive airway pressure (CPAP) \& walking exercise on fatigue severity, liver enzymes and sleeping quality in patients with...

Sponsor: Ahram Canadian UniversityEnrolling: 401 location
RECRUITINGPhase 1NCT07358546

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI)...

Sponsor: GlaxoSmithKlineEnrolling: 322 locations
RECRUITINGNCT06015620

Comorbidities Resolution After MGB Surgery and Change in Body Composition

This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in...

Sponsor: All India Institute of Medical Sciences, BhubaneswarEnrolling: 351 location
RECRUITINGNCT05816915

Lifestyle Modification in the Treatment of NAFLD.

The project will study the impact of individually tailored lifestyle counselling compared to standard care on the parameters of NAFLD/NASH in patients with metabolic syndrome. The...

Sponsor: General University Hospital, PragueEnrolling: 1001 location
RECRUITINGNCT03875625

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention

The study is aimed * To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery. * To test...

Sponsor: Chinese University of Hong KongEnrolling: 801 location
RECRUITINGPhase 2NCT07288138

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO)...

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on...

Sponsor: EccogeneEnrolling: 16020 locations
RECRUITINGEarly Phase 1NCT07185932

Efficacy and Safety of Rifaximin in Treating MAFLD

Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms...

Sponsor: Shanghai Changzheng HospitalEnrolling: 401 location
RECRUITINGNCT06586281

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared...

Sponsor: University of California, San DiegoEnrolling: 201 location
RECRUITINGNCT06413069

Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)

Tree nuts - such as almonds - contribute to beneficial effects of the Mediterranean diet on risk for cardiovascular events, type 2 diabetes, dyslipidemia, hypertension,...

Sponsor: Charite University, Berlin, GermanyEnrolling: 1501 location
RECRUITINGNCT06939569

An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable. In recent years, the incidence of IBD has...

Sponsor: Shanghai East HospitalEnrolling: 3371 location
RECRUITINGNCT04054310

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.

Sponsor: PerspectumEnrolling: 2257 locations
RECRUITINGNCT06676813

Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.

The aims of this study are as follows: To compare the role of alternate-day fasting over standard medical management alone to reverse NASH.

Sponsor: Institute of Liver and Biliary Sciences, IndiaEnrolling: 721 location
RECRUITINGPhase 1NCT06354088

Human Models of Selective Insulin Resistance: Alpelisib, Part I

The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study...

Sponsor: Columbia UniversityEnrolling: 321 location
RECRUITINGPhase 4NCT06989723

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes...

Sponsor: Seoul National University Bundang HospitalEnrolling: 1201 location
RECRUITINGNCT04365855

The Olmsted NAFLD Epidemiology Study (TONES)

Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized...

Sponsor: Mayo ClinicEnrolling: 8001 location
RECRUITINGNCT06195943

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With...

This study will be a pilot study to evaluate the feasibility, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously...

Sponsor: Milton S. Hershey Medical CenterEnrolling: 201 location
RECRUITINGPhase 2NCT06355310

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors...

Sponsor: Justin RyderEnrolling: 401 location
RECRUITINGNCT06403332

Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal...

Excessive alcohol use is a leading risk factor for preventable disability and death. Alcohol-related liver disease (ALD) is one of the better-known detrimental consequences of...

Sponsor: Hospital Universitari Vall d'Hebron Research InstituteEnrolling: 3502 locations
RECRUITINGPhase 2NCT07481734

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in...

Sponsor: Hudson BiotechEnrolling: 1201 location
RECRUITINGNCT05890365

Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

The investigators recently demonstrated a increase in liver fat in early middle-aged LBW compared to normal birth weight (NBW) men, and 20% of the LBW - but none of the normal...

Sponsor: Steno Diabetes Center CopenhagenEnrolling: 3001 location
RECRUITINGNCT03073343

A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a...

Sponsor: Southern California Institute for Research and EducationEnrolling: 481 location
RECRUITINGNCT05597709

Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by...

Sponsor: Wuxi Hisky Medical Technology Co LtdEnrolling: 29001 location
RECRUITINGNCT05335603

An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis

Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is...

Sponsor: University of CopenhagenEnrolling: 3351 location
RECRUITINGPhase 2NCT06564584

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with...

Sponsor: OrsoBio, IncEnrolling: 304 locations
RECRUITINGNCT07330830

Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population...

Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and...

Sponsor: Centre Hospitalier Universitaire de la GuadeloupeEnrolling: 6003 locations
RECRUITINGNCT06512701

Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease

Excessive or insufficient levels of vitamins in the body can affect health. With the prevalence of obesity and MetS, NAFLD has become the leading cause of chronic liver disease...

Sponsor: First Affiliated Hospital of Zhejiang UniversityEnrolling: 40001 location
RECRUITINGNCT07122700

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory...

Sponsor: Foundation for the National Institutes of HealthEnrolling: 4004 locations
RECRUITINGNCT04785937

Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD Patients

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition, and when fatty liver is associated with inflammation and hepatocellular injury (steatohepatitis), it can...

Sponsor: Azienda USL Reggio Emilia - IRCCSEnrolling: 501 location
RECRUITINGPhase 1NCT05945537

A Study of INI-822 in Healthy Volunteers and Participants with Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers...

Sponsor: Inipharm Australia Pty LtdEnrolling: 1047 locations
RECRUITINGNCT06138821

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the...

Sponsor: Pichamol Jirapinyo, MD, MPHEnrolling: 1322 locations
RECRUITINGNCT06704321

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content,...

Sponsor: ValbiotisEnrolling: 701 location
RECRUITINGPhase 3NCT06493799

In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human...

Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)

Sponsor: Green Cross WellbeingEnrolling: 2261 location
RECRUITINGPhase 2NCT07308548

A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )

Primary Objective: • To evaluate the efficacy of HP515 tablets in participants with non-alcoholic fatty liver disease. Secondary objectives: * To evaluate the safety of HP515...

Sponsor: Hinova Pharmaceuticals Inc.Enrolling: 802 locations
RECRUITINGNCT06275906

Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.

The study in question is an interventional study with nutritional intervention. The aim of the study is to evaluate whether the adoption of two different models of Mediterranean...

Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisEnrolling: 601 location
RECRUITINGNCT06495333

Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of liver disease worldwide. The condition is defined by fat accumulation exceeding 5% of...

Sponsor: Fundacion de Investigacion Science and EducationEnrolling: 1001 location
RECRUITINGNCT06814600

Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients

Non-alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disease characterized by the presence of more than 5% of steatosis in hepatocytes of individuals who consume...

Sponsor: Centre Hospitalier Universitaire Saint PierreEnrolling: 1501 location

Showing 50 of 100 trials.Search all NASH trials